Wish i had more cash in my account when i first bought then i wouldn't need to top up hahahaha...It will still go up further so it's best to hold longer unless you need cash asap..
What @CertifiedAnalyst told is true, 90% of investor doesn't do research, mostly pump and dumb, they see muhibbah, they see "oh its airport business! like airasia! will recover, lets buy!" , you think they check the balance statement, the debt, the profits, pe ratio, annual reports and all that?
so even if muhibbah is in trouble right now, they will still buy because they see people pumping, so they think they can join in the ride, well chances are you're buying at the peak.
Wow, amazing how selfish ppl are. Put aside your great technical points, when youre in the boat, you keep quiet. When you just jump off the boat and take profit, you condemn how bad the counter is.. :)... But truthfully, in share market you néed be selfish and cunning like F91 so you can buy back when price drop.
FYI, Muhibbah has an incredibly strong balance sheet for a construction company! Far stronger than Gamuda, IJM etc....go & check if you don't believe! For that reason alone, I resisted the temptation to take quick profits.
I learnt a lesson from 2013 when I didn't buy the 3,000 shares selling at 80c in March '13 because of the loss-making qtr announcement in Feb, then it kept on going up & up & up to $2.50 +.
On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. The volunteers all got two doses, but in some cases the first dose was only half strength. Surprisingly, an initial half-strength dose led to 90 percent efficacy, while two standard-dose shots led only to 62 percent efficacy. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response.
The preliminary analysis also indicated that the vaccine didn’t just reduce cases of Covid-19 with symptoms. It also reduced the number of asymptomatic cases. That finding may mean that the vaccine will be good at reducing the transmission of the virus from person to person. Another advantage of the vaccine is that it can be kept in a refrigerator, unlike Pfizer and Moderna’s vaccines, which have to be frozen.
Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. The United States awarded the project $1.2 billion in support for 300 million doses. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
dompeilee
11,888 posts
Posted by dompeilee > 2020-11-17 14:40 | Report Abuse
WooHOOOOO!!!! Reaching my 1st target of 1.09!!! Truly meriah dan muhibbah!!! =)